By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
NEW YORK (Reuters Health) – In patients with potentially resectable colorectal liver metastases, the use of combined PET and CT imaging (PET-CT) identifies those with occult extrahepatic disease…
Recent Videos in Reuters Health • The Doctor’s Channel Newscast Page 10
NEW YORK (Reuters Health) – Intraperitoneal chemotherapy may significantly improve long-term survival in ovarian cancer patients, a new study found. Data from 876 patients followed for a median…
NEW YORK (Reuters Health) – The risk of arterial thromboembollic events related to bevacizumab treatment of colorectal cancer (CRC) in older patients is moderate in general practice, and…
NEW YORK (Reuters Health) – In cancer patients with a central venous catheter (CVC), the occurrence of a related infection or thrombosis can often be resolved while the…
NEW YORK (Reuters Health) – The rate of incidental thyroid cancer detected among patients who undergo thyroidectomy for apparently benign disease is unexpectedly high, especially in cases of…
NEW YORK (Reuters Health) – Patients with acute myeloid leukemia (AML) who do not receive a stem-cell transplant during first remission and then relapse have a fair chance of…
NEW YORK (Reuters Health) – Anticoagulant use may be a predictor of overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel, retrospective data suggest. The…
NEW YORK (Reuters Health) – Transplantation of hematopoietic cells from a donor with a single matched HLA haplotype, combined with post-transplant cyclophosphamide, may be a good alternative when…
NEW YORK (Reuters Health) – Patients with follicular non-Hodgkin lymphoma that has transformed into aggressive-histology lymphoma do better when treated with high-dose chemotherapy followed by autologous stem-cell transplantation…
NEW YORK (Reuters Health) – Reducing exposure to alkylating agents in patients with Hodgkin lymphoma is key to reducing the risk of developing therapy-related acute myeloid leukemia or…
NEW YORK (Reuters Health) – Agents that target the mTOR axis, which have become particularly important in the treatment of advanced renal cell carcinoma (RCC), have significant adverse…
